Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

Differentiation induction is currently considered as an alternative strategy for treating chronic myelogenous leukemia (CML). Our previous work has demonstrated that Sprouty-related EVH1 domainprotein2 (Spred2) was involved in imatinib mediated cytotoxicity in CML cells. However, its roles in growth and lineage differentiation of CML cells remain unknown. In this study, we found that CML CD34+ cells expressed lower level of Spred2 compared with normal hematopoietic progenitor cells, and adenovirus mediated restoration of Spred2 promoted the erythroid differentiation of CML cells. Imatinib could induce Spred2 expression and enhance erythroid differentiation in K562 cells. However, the imatinib induced erythroid differentiation could be blocked by Spred2 silence using lentiviral vector PLKO.1-shSpred2. Spred2 interference activated phosphorylated-ERK (p-ERK) and inhibited erythroid differentiation, while ERK inhibitor, PD98059, could restore the erythroid differentiation, suggesting Spred2 regulated the erythroid differentiation partly through ERK signaling. Furthermore, Spred2 interference partly restored p-ERK level leading to inhibition of erythroid differentiation in imatinib treated K562 cells. In conclusion, Spred2 was involved in erythroid differentiation of CML cells and participated in imatinib induced erythroid differentiation partly through ERK signaling.

CML is a clonal hematopoietic stem cell disorder that the malignant clone progressively loses the capacity for terminal differentiation. Thus, differentiation induction has been considered as an alternative approach for CML therapy. Some valuable progress has been achieved in biological or chemical agents that could induce terminal differentiation [10][11][12][13]. It has been reported that low concentration of imatinib induces proliferation arrest and erythroid differentiation of CML cells [14,15]. The RAS-ERK pathway is known to contribute to myeloid differentiation of CML cells [16]. Notably, CML treatment lead to terminal differentiation of leukemia cell lines or primary cells, as well as proliferation arrest and cell apoptosis, by regulating RAS-ERK cascade [17][18][19][20].
Sprouty-related EVH1 domainprotein 2 (Spred2) proteins are identified as a family of membrane-associated negative regulators of growth factor-induced RAS-ERK activation [21]. Our previous studies demonstrated that Spred2, a subset of Spreds family, was involved in imatinib-induced cytotoxicity in CML cells. Imatinib treatment upregulates Spred2 expression, leading to apoptosis and growth arrest in CML cells [17]. However, whether Spred2 is implicated in CML cell differentiation remains unclear. In this study, we clarified the expression and potential roles of Spred2 protein in erythroid differentiation of CML cells and its mechanisms.
The bone marrow (BM) samples were obtained from healthy donor or CML patients undergoing diagnostic procedures at Peking university first hospital. Written informed consent was obtained from each healthy donor and CML patient. All the procedures were approved by the Ethics Committee of Beijing Institute of Radiation Medicine. Mononuclear cells were isolated from heparinized samples by centrifugation through a Ficoll-Hypaque density gradient (Amersham Biosciences, Piscataway, NJ, USA). Then, CD34 + cells were isolated by using human CD34 positive selection kit (Stem Cell Technology, Vancouver BC, Canada).
293T cells (ATCC) were cultured in RPMI 1640 (Sigma) medium supplement with 10% FCS (Hyclone) and plated at 6×10 6 cells per 10-cm plate 1 day before transfection. Transfer vector PLKO.1-shSpred2 or PLKO.1-shScramble, packing plasmid psPAX2 and envelope plasmid pMD2.G were co-transfected by using the phosphate coprecipitation kit (Promega, Madison, WI, USA) according to manufacturer's protocol and culture medium was replaced by fresh growth medium 6h after transfection. The virus containing media were collected at 36h and 48h after transfection. Viruses were purified and concentrated by PEG, followed by determination of viral titers on HT1080 cells.

Virus transduction
Before transduction, CD34 + cells were cultured in SFEM medium (Stem Cell Technologies. Inc., Vancouver, Canada) supplement with 50ng/ml stem cell factor (SCF), 100ng/ml thrombopoietin (TPO), 100ng/ml FMA-like tyrosine kinase 3 ligand (Flt-3L), 100 ng/ml interleukin (IL) -6, and 50ng/ml IL-3 (Peprotech, Rocky Hill, NJ) for 48 hours. CD34 + cells and K562 cells were plated in 24-well plate at a density of 2×10 5 per well, and then were infected by lentiviral vectors at multiplicity of infection (MOI) of 10 or by adenoviral vector at MOI of 150. The gene transduction efficiency of lentiviral vectors, indicated by RFP expression, was detected by flow cytometry (Becton Dickinson, Mountain View, CA). And, the mRNA expression of Spred2, CD235a and differentiation related transcription factors GATA1 were also detected in CD34 + cells and K562 cells by using real-time reverse transcription polymerase chain reaction (RT-PCR).

Colony-Forming Cell (CFC) assay
Two days after transduced by lentiviral vectors, CD34 + cells were plated in 24-well plate at a density of 500 per well, and cultured in 1% methylcellulose medium supplemented with 30% FCS, 50ng/ml SCF, 50ng/ml IL-3, 200ng/ml G-CSF, 200ng/ml GM-CSF, 63μM β-mercaptoethanol and 3 unit/ml erythropoietin, which is formulated to support optimal growth of erythroid progenitors (CFU-E and BFU-E), granulocyte-macrophage progenitors (CFU-GM, CFU-G, and CFU-M) and multi-potential granulocyte, erythroid macrophage and megakaryocyte progenitor (CFU-GEMM). Fourteen days later, the presence of colonies (>40 cells) was counted and scored. The colonies formation scoring and erythroid colonies scoring were calculated from the numbers of colonies/total number of cells seeded.

Real-time RT-PCR
Total RNA was isolated from CD34 + cells or K562 cells by using TRIzol reagent (Invitrogen, Carlsbad, CA), and the cDNA was synthesized using a First Strand cDNA Synthesis Kit (Thermo Scientific, Wilmington, DE) according to the manufacturer's instructions. Then, the mRNA expression was quantified by using SYBR Green Real-Time kit (Takara Bio Inc., Otsu, Shiga, Japan) on 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The primers for homo sapiens CD235a, spred1, spred2, gata binding protein 1 (globin transcription factor 1) (GATA1) and beta-actin (β-actin) were shown in Table 1. And the expression levels were normalized by β-actin or the target gene expression at day 0 after cultured in differentiation medium. The results were showed as the mean± s.d. of triplicates and were representative of three independent experiments.

Western blotting
After indicated treatment, Spred2 over-expressed or slicenced K562 cells were collected and the protein was extracted. Then, the expression of Spred2 was detected by rabbit anti-human Spred2 antibody (Sigma). And, the activation of MAPK signalling pathway was detected by anti-phospho-ERK1/2 antibody and anti-ERK-1/2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 6h, 12h, 18h, 24h after treatment with 10mg/ml PMA or at 1h after treated by 0.1, 0.5 or 1.0μM imatinib.

Statistical analysis
All results are representative of at least three independent experiments. Values were presented as the mean ± SD. One-way analysis of variance was used to compare the means of two or more experimental groups, followed by the Dunnett post hoc test. The difference was considered to be statistically significant as p<0.05.

Spred2 was involved in imatinib induced erythroid differentiation of K562 cells
We investigated the influence of imatinib treatment on Spred2 expression of K562 cells using real-time RT-PCR, and the results showed that Spred2 could be induced by imatinib (Fig. 3A). PLKO.1-shSpred2 transduction inhibited Spred2 expression obviously in K562 cells, while had no effect on Spred1 (Fig. 3B). Interestingly, Spred2 interference could partially block imatinibinduced erythroid differentiation of K562 cells. As shown in Fig. 3C-3D, imatinib treatment increased CD235a expression in K562 cells, whereas Spred2 silence downregulated the expression of CD235a both in presence or absence of imatinib. Furthermore, mRNA expression of CD235a (Fig. 3E) and GATA1 (Fig. 3F) was also downregulated in PLKO.1-sh-Spred2 transduced cells. These results indicated that Spred2 was involved in imatinib induced erythroid differentiation of CML cells.

Spred2 over-expression enhanced erythroid differentiation induced by imatinib in K562 cells
The effects of Spred2 over-expression on erythroid differentiation of K562 cells were also investigated in this study. Ad5/F11p-Spred2 transduction increased Spred2 expression of K562 cells in absence or presence of imatinib (Fig. 4A). Our results showed that imatinib or Spred2 overexpression could increase the CD235a and GATA1 expression, while the combination of imatinib and Spred2 over-expression was much more impressive (Fig. 4B-4E), suggesting the combination might be a potential strategy for CML therapy. Spred2 regulated erythroid differentiation through targeting ERK signaling in K562 cells Spred2 mediated inhibition of ERK signaling has been reported in K562 cells. In this study, we demonstrated that Spred2 could inhibit PMA induced ERK phosphorylation, while Spred2 interference enhanced PMA induced activation of ERK signaling (Fig. 5A-B). It has been demonstrated above that Spred2 silence could inhibit erythroid differentiation of K562 cells. However, ERK inhibitor, PD98059, partly restore the erythroid differentiation in PLKO.1-shSpred2 transduced K562 cells, suggesting PLKO.1-shSpred2 inhibit erythroid differentiation partly through ERK signaling (Fig. 5C-5D). Furthermore, we also found that imatinib treatment resulted in inactivation of ERK signaling, while Spred2 silence partly restored ERK phosphorylation in imatinib treated K562 cells (Fig. 5E), indicating that imatinib and Spred2 might synergistically inhibit the ERK signaling to regulate erythroid differentiation of K562 cells. Moreover, Spred-2 knockdown also increases Ras expression in K562 cells treated with imatinib, which is consistent to the changes of ERK signals (Fig. 5F).

Discussion
Spred proteins, a class of selective inhibitors of the Ras-ERK cascade, inhibit cell motility, proliferation, tumor metastasis and Rho-mediated actin reorganization [22][23][24]. Spred2, a member of Spred proteins, is expressed in the aorta-gonad-mesonephros (AGM) region and functions as a negative regulator in AGM hematopoiesis [25]. In this study, we demonstrated that Spred2 was involved in erythroid differentiation of CML cells induced by imatinib. Spred2 lies downstream of FoxO3a, which was involved in imatinib-induced cytotoxicity and erythroid differentiation [26][27][28]. Restored expression of Foxo3a and Spred1 was induced by tyrosine kinase inhibitors, such as imatinib and disatinib [29].Previous reports also showed that Spred2 down-regulation in hematopoietic stem cells of FoxO3a-deficient mice hyper-activated ERK and resulted in hyper-proliferation of neutrophils [30]. We also found the implication of Spred2 in imatinib-induced cell killing of CML cells [17]. However, the role of Spred2 in regulation of erythroid differentiation of CML cells and its mechanisms remain to be fully clarified.
CML is clinically characterized by three phases: an initial chronic phase displaying almost normal myeloid differentiation, followed by an accelerated phase and then the final blast crisis, in which myeloid and lymphoid blasts failed to differentiate and led to abnormal accumulation of immature leukemic blast cells in blood and bone marrow [31]. Our data showed that the expression of Spred2 was down-regulated significantly in CML CD34 + cells, and Spred2 over-expression could restore the ability of erythroid differentiation. These data indicated that Spred2 was involved in differentiation of CML cells and might be a candidate target for CML therapy.
Imatinib could induce both cytotoxicity and erythroid differentiation of CML cells [17,32,33]. We further investigated whether Spred2 was involved in imatinib induced erythroid differentiation in CML cells. K562 cell is a bipotent cell line established from a patient in a blast crisis of chronic myeloid leukemia, it possesses variable capacities of differentiation toward erythroid and megakaryocytic cell lineages. We assayed the effects of imatinib and Spred2 on differentiation potential of CML cells. Our results showed that Spred2 over-expression enhanced the erythroid differentiation induced by imatinib, whereras Spred2 silence partly blocked this process. We also demonstrated that imatinib induced Spred2 expression both in primary CML and K562 cells.
Several reports suggested that blockade of BCR-ABL and downstream Ras-ERK pathway by imatinib, geldanamycin, RNA interference of BCR-ABL, herbimycin A, U0126, butyrateand ara-C caused erythroid differentiation of K562 cells [8,[34][35][36][37][38]. Others indicated that inhibition of signaling through ERK in K562 cells might be needed to enter the erythroid differentiation process, while the erythroid differentiation after initiation could be enhanced by both activation and inhibition of ERK signaling depending on inducing compound [36]. Based on the previous data that Spred2 inhibited phosphorylated-ERK (p-ERK) in K562 cells, we further demonstrated that Spred2 interference could partly reverse imatinib induced down-regulation of p-ERK level. Our data also showed that MEK-1 inhibitor, PD98059, not only enhanced the erythroid differentiation in K562 cells, but also reversed PLKO.1-sh-Spred2 induced inhibition of erythroid differentiation, indicating that Spred2 interference blocks erythroid differentiation partly through activation of ERK signaling.

Conclusion
We here demonstrated that Spred2 participated in erythroid differentiation of CML cells. Spred2 was involved in imatinib induced erythroid differentiation partly through inhibition of ERK signaling. These data might provide valuable insights into the mechanisms of differentiation of CML cells and present novel target for developing therapy strategies.